Enterprise Value
-87.57M
Cash
264.1M
Avg Qtr Burn
-21.95M
Short % of Float
3.86%
Insider Ownership
9.52%
Institutional Own.
83.40%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nulabeglogene autogedtemcel (nula-cel) (GPH101) Details Sickle cell disease | Failed Discontinued |